Yelena Y. Janjigian, MD, FASCO, on CLARITY-Gastric 01: Sonesitatug Vedotin in CLDN18.2-Positive Gastroesophageal Cancer

November 02, 2026

Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center—a co-chair of a Presidential Symposium at the ESMO Congress 2026—reviews results from the phase III trial that looked at the CLDN18.2-targeting antibody-drug conjugate sonesitatug vedotin vs investigator’s choice of therapy after at least one prior therapy for gastroesophageal cancer expressing CLDN18.2 in ≥ 25% tumor cells with membranous staining at any intensity (Abstract LBA7). 

Related Content